Sarah C. Brüningk

dblp:278/8516 · DBLP profile ↗
← Back
2ranked-venue papers
0as first author
2since 2021 · last 2026
0000-0003-3176-1032ORCID · verified

Domains — the database's venue-derived domains; a paper can count in several

Applied, interdisciplinary, general and emerging computing · 2 · 2 since 2021

Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.

Interdisciplinary, comprehensive, and emerging computing
2 papers
Bioinformatics and computational biology · 93% Medical and health informatics · 7%

Topics — the 6 heaviest of 6, each with the papers that count most for it

TopicWeightPapersLastEvidence papers
Bioinformatics and computational biology
cancer genomics
1.012026
Joint representation learning for oncology applications · Bioinform. 2026
Bioinformatics and computational biology
multi-omics data integration
1.012026
Joint representation learning for oncology applications · Bioinform. 2026
Bioinformatics and computational biology
biomarker discovery
0.812024
Biomarker identification by interpretable maximum mean discrepancy · Bioinform. 2024
Bioinformatics and computational biology
feature selection
0.812024
Biomarker identification by interpretable maximum mean discrepancy · Bioinform. 2024
Bioinformatics and computational biology › biostatistics › statistical bioinformatics
statistical genomics
0.812024
Biomarker identification by interpretable maximum mean discrepancy · Bioinform. 2024
Medical and health informatics
oncology
0.312026
Joint representation learning for oncology applications · Bioinform. 2026

Methods — techniques the papers use, named apart from their topics

unsupervised manifold alignment · 1.0joint multidimensional scaling · 1.0sparse optimization · 0.8shapley additive explanations · 0.8maximum mean discrepancy · 0.8
YearPublicationVenuePosition
2026 Joint representation learning for oncology applications
abstract
MOTIVATION: The integration of tumour imaging data and molecular sequencing information can advance our understanding of cancer biology by combining complementary perspectives of tumour phenotype and genotype. However, integrating multi-modal data across heterogeneous and high-dimensional data domains remains a significant computational challenge. RESULTS: Here, we introduce an unsupervised manifold alignment approach for real-world data integration based on Joint Multidimensional Scaling (Joint MDS) and extend it to a three-modality framework (Joint MDS3). We apply this method to integrate radiomic features from magnetic resonance imaging (MRI) with transcriptomic, epigenomic, and copy number variation (CNV) data from patients with glioblastoma multiforme (GBM) and lower-grade gliomas (LGG). Compared to baselines such as Pamona and single-cell optimal transport (SCOTv2), Joint MDS consistently outperforms baseline Pamona in cases and achieves competitive performance relative to baseline SCOTv2, outperforming its fraction of samples closer to an incorrect match (FOSCTTM) in four out of six cases. Joint MDS attains an average label transfer accuracy of 74.8%, approximately 4% higher than that of Pamona and SCOTv2, and reduces FOSCTTM to 51% or less across real-world datasets. We further demonstrate our extension JointMDS3 on both synthetic and real-world examples. Our results highlight the potential of Joint MDS to enhance the integration of diverse data types into a unified representation, ultimately advancing computational approaches in complex diseases. AVAILABILITY AND IMPLEMENTATION: The implementation of our work is available at gitlab.ethz.ch/BMDSlab/publications/oncology/joint-representation-learning-for-oncology-applications and archived at doi.org/10.5281/zenodo.17219404.
Tanya Nandan, Bowen Fan, Samuel Håkansson, Catherine R. Jutzeler, Sarah C. Brüningk
Bioinform.5
2024 Biomarker identification by interpretable maximum mean discrepancy
abstract
MOTIVATION: In many biomedical applications, we are confronted with paired groups of samples, such as treated versus control. The aim is to detect discriminating features, i.e. biomarkers, based on high-dimensional (omics-) data. This problem can be phrased more generally as a two-sample problem requiring statistical significance testing to establish differences, and interpretations to identify distinguishing features. The multivariate maximum mean discrepancy (MMD) test quantifies group-level differences, whereas statistically significantly associated features are usually found by univariate feature selection. Currently, few general-purpose methods simultaneously perform multivariate feature selection and two-sample testing. RESULTS: We introduce a sparse, interpretable, and optimized MMD test (SpInOpt-MMD) that enables two-sample testing and feature selection in the same experiment. SpInOpt-MMD is a versatile method and we demonstrate its application to a variety of synthetic and real-world data types including images, gene expression measurements, and text data. SpInOpt-MMD is effective in identifying relevant features in small sample sizes and outperforms other feature selection methods such as SHapley Additive exPlanations and univariate association analysis in several experiments. AVAILABILITY AND IMPLEMENTATION: The code and links to our public data are available at https://github.com/BorgwardtLab/spinoptmmd.
Michael F. Adamer, Sarah C. Brüningk, Dexiong Chen, Karsten M. Borgwardt
Bioinform.2